SCHEMBL2689901

SCHEMBL2689901

COc1ccc(-n2c(C)nc3cc(-c4nc5ccccc5o4)ccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.52
▸ PTPN2 P17706 2/20 0.47
▸ PTPN1 P18031 2/20 0.47
▸ PTPN5 P54829 2/20 0.47
▸ ALDH1A1 P00352 11/20 0.47
▸ HPGD P15428 9/20 0.47
▸ TP53 P04637 3/20 0.46
▸ KDM4E B2RXH2 7/20 0.46
▸ RAB9A P51151 6/20 0.46
▸ HSD17B10 Q99714 5/20 0.46
▸ MAPK1 P28482 4/20 0.46
▸ USP2 O75604 3/20 0.46
▸ TSHR P16473 3/20 0.46
▸ GAA P10253 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ P2RY14 Q15391 1/20 0.46
▸ MAPT P10636 4/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ STAT3 P40763 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687461 0.90 THRB (0.54) NPC1PTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2686770 0.89 MAPK1 (0.55) NPC1ALDH1A1HPGDTP53KDM4E
SCHEMBL2687352 0.87 NPC1 (0.46) NPC1PTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2686599 0.83 NPC1 (0.58) NPC1PTPN2PTPN1PTPN5ALDH1A1
SCHEMBL1199992 0.78 PTPN2 (0.68) NPC1PTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2688110 0.78 NPC1 (0.55) NPC1ALDH1A1HPGDTP53KDM4E
SCHEMBL541002 0.77 HTT (0.70) NPC1ALDH1A1HPGDTP53KDM4E
SCHEMBL2688761 0.75 NPC1 (0.46) NPC1PTPN2PTPN1PTPN5ALDH1A1
SCHEMBL2688885 0.75 NPC1 (0.50) NPC1ALDH1A1HPGDTP53KDM4E
SCHEMBL2686759 0.75 NPC1 (0.49) NPC1PTPN2PTPN1PTPN5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 — — EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 NPC1 525/4885PTPN2 2427/4885PTPN1 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback